Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in ...
EQT Life Sciences’ ImCheck Therapeutics to be acquired | EQT
ImCheck Therapeutics Secures EMA Orphan Drug Designation - Investors ...
Ipsen strikes €1bn deal to acquire biotech ImCheck Therapeutics
ImCheck Appoints Thomas Civik as Independent Chairman of the Board ...
ImCheck Therapeutics Presents Promising Data from Phase I/IIa EVICTION ...
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology ...
Ipsen Acquires ImCheck Therapeutics, Enhancing its Oncology Leadership ...
Ipsen Acquires ImCheck Therapeutics for €1 Billion to Advance Novel AML ...
ImCheck Therapeutics’ 48 million fundraising - Lawyer Monthly
With stacked to-do list, ImCheck checks off next funding round ...
ImCheck raises Series B funds to develop gamma delta therapies ...
ImCheck scores $22.4m in French funding to develop cancer antibody
Ipsen Optimizes its 2025 Path and Accelerates in Oncology with ImCheck ...
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 ...
ImCheck Therapeutics Pitch Deck Used to Raise Series C - Business Insider
ImCheck Therapeutics | Gimv
ImCheck Therapeutics on LinkedIn: Trophées des futures licornes ...
Congratulations to Dr. Stephan Braun and the entire ImCheck ...
We are delighted to share the news that Imcheck Therapeutics ...
Ipsen to acquire ImCheck Therapeutics, in Andera Partners’ portfolio ...
ImCheck Therapeutics on LinkedIn: #aacr21 #ict01 #tcell #monoclonal # ...
Imchecktherapeutics.com | ImCheck Therapeutics
We are proud to announce that ImCheck Therapeutics, a Pureos ...
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of ...
ImCheck Therapeutics SAS raises €48m - European Biotechnology Magazine
French ImCheck get´s a USD103m check by Pfizer and a pack of VCs ...
ImCheck Therapeutics on LinkedIn: EVICTION-2 at SITC 2022
ImCheck Therapeutics: Imcheck Therapeutics
Celebrating major success with ImCheck Therapeutics acquisition at up ...
ImCheck Therapeutics on LinkedIn: #esmo23 #imchecktherapeutics #esmo23 ...
ImCheck Therapeutics on LinkedIn: Landing in Marseille? ImCheck ...
ImCheck Therapeutics posted on LinkedIn
ImCheck Reports Durable Responses and Early Overall Survival Signal ...
ImCheck Therapeutics on LinkedIn: #patientresponse #evictiontrial # ...
#chiefmedicalofficer #immunooncology #mrna | ImCheck Therapeutics
Ipsen Puts Up $1.6B To Absorb ImCheck for Mid-Stage Leukemia Antibody ...
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of ...
ImCheck Therapeutics on LinkedIn: #gdtcells #danielolive #renehoet
Ipsen Acquires ImCheck Therapeutics, Accelerating ICT01 Development in ...
News: Imcheck Therapeutics
We are pleased to announce the final closing of ImCheck Therapeutics ...
ImCheck Therapeutics Receives Orphan Drug Designation for AML Treatment ...
ImCheck Therapeutics on LinkedIn: #ict01 #aacr21 #γδtcell # ...
Ipsen acquires ImCheck in US$1bn deal - European Biotechnology Magazine
Ipsen Expands Cancer Portfolio: Ipsen Acquires ImCheck Therapeutics in ...
#immunooncology | ImCheck Therapeutics
ImCheck AML Therapy Shows High Remission at ASCO 2025
ImCheck Therapeutics on LinkedIn: https://lnkd.in/eZCmPcee
Marina Iché on LinkedIn: ImCheck Presented Updated Positive Data from ...
ImCheck Therapeutics data at ASCO points to promise for T-cell therapy ...
ImCheck Therapeutics is proud to be part of the FT120 for the fourth ...
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose ...
Ipsen Acquires ImCheck Therapeutics to Strengthen Oncology Pipeline ...
Clinical focus: Imcheck Therapeutics
ImCheck raises €96M in funding round
Imcheck Raises €96 Million in Series C Financing
Ipsen acquires ImCheck Therapeutics for AML treatment - Drug Discovery ...
Ipsen to buy ImCheck for €350M to get ‘superfamily’ of immunotherapies
ImCheck Therapeutics | LinkedIn
ImCheck | EQT Portfolio
Today, on International Women's Day, ImCheck Therapeutics proudly ...
Andera Partners on LinkedIn: ImCheck Closes Upsized EUR 96 Million (USD ...
News - Page 2 of 4: Imcheck Therapeutics
ImCheck selected as laureate of the new French Tech 2030 program ...
Magali Colazet - R&D Scientist at ImCheck Therapeutics | The Org
Oncologie : La biotech marseillaise ImCheck lève un montant record de ...
ImCheck lève 96 millions d'euros, un record pour une BioTech française
ImCheck lève 48 millions d'euros pour booster son immunothérapie | Les ...
ImCheck Therapeutics à l’assaut d’une nouvelle génération d’anticancéreux
Traitement contre le cancer : Imcheck Therapeutics lève 48 millions d ...
ImCheck Therapeutics lève près de 100 millions pour valider sa thérapie ...
ImCheck bat des records en série C | CFNEWS
Imchecktherapeutics.com: Imcheck Therapeutics
About ICT01: Imcheck Therapeutics
Imcheck Therapeutics, une biotech à la pointe de la recherche
Imcheck complète son tour de table avec 6 millions d'euros de Pureos ...
New Immuno-oncology Biotech Gets a €20M Series A Funding Boost
14 techbio soonicorns to watch | Sifted
Ipsen expands oncology portfolio with €1B acquisition of French biotech ...
Carla Cano on LinkedIn: 20230314_ImCheck_AACR_Poster_EVICTION-2.pdf
(PDF) ImCheck3 Installation and User’s Guide - LosBurnslosburns.com ...
Ipsen buys ImCheck, adding mid-stage leukaemia drug | pharmaphorum
#oncology #immunotherapy #immunooncology #precisiononcology #imcheck # ...
Equilar alert: Congratulations Thomas Civik on your appointment to the ...
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of ...
#ebvcgang #healthcare #health #seriesc #imcheck #therapeutics # ...
#ash24 #llstap #immunotherapy #ict01 #aml #leukemia #cancerresearch ...
Understanding Cytokine Responses in Cancer Patients That Develop Immune ...
How to Use Flow Cytometry for Cell Viability Assays
Top 75 medical and healthcare startups in France 2026
Green check mark icon with circle, tick box, check list circle frame ...
Healthcare companies: we work alongside the most promising among them ...
生物技术公司ImCheck Therapeutics完成5300万美元的B轮融资，将用于其单克隆抗体ICT01的1期临床试验-动脉网
ImCheck's Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases
